Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$121.11 - $216.05 $475,598 - $848,428
-3,927 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$248.56 - $389.34 $976,095 - $1.53 Million
3,927 New
3,927 $1.06 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Investment Management Corp Of Ontario Portfolio

Follow Investment Management Corp Of Ontario and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Investment Management Corp Of Ontario, based on Form 13F filings with the SEC.

News

Stay updated on Investment Management Corp Of Ontario with notifications on news.